Quick Summary:
As the global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs market prepares for steady growth in the coming years, it is crucial to stay informed and ahead of the sector trends and trajectories. Our newly updated market research report meticulously analyzes the growing $3.5 billion MRSA Drugs market and forecasts it to reach a significant valuation of $4.4 billion by 2030, ensuring you are equipped with the information needed to make judicious strategic decisions for your business in the healthcare field.
We've put the magnifying glass to the key geographic markets, including the US, China, Japan and Canada, and major competitors in the MRSA drugs industry, to provide you with in-depth insights and assessments. This report keeps you abreast of market dynamics, competitive landscapes, and geographic trends crucial to your business growth and expansion. Enhancing the value of the report, complimentary updates for one year, access to historical data, and collaborative bespoke updates are included, ensuring that you always have the most up-to-date and contextually rich information at your fingertips.
Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market to Reach $4.4 Billion by 2030
The global market for Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs estimated at US$3.5 Billion in the year 2022, is projected to reach a revised size of US$4.4 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2022-2030. Lipopeptide, one of the segments analyzed in the report, is projected to record 3% CAGR and reach US$1.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Oxazolidinone segment is readjusted to a revised 3.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1 Billion, While China is Forecast to Grow at 3.1% CAGR
The Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs market in the U.S. is estimated at US$1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$791.7 Million by the year 2030 trailing a CAGR of 3.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3% and 2.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.Select Competitors (Total 41 Featured) -
- Allergan PLC
- Basilea Pharmaceutica Ltd.
- Merck & Co., Inc.
- Pfizer, Inc.
- The Medicines Company
- Theravance Biopharma, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs?
What is the growth rate of the Global Market for Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs?
What is the forecasted size of the Global Market for Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs?
Who are the key companies in the Global Market for Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs?
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 3.5 Billion |
| Forecasted Market Value ( USD | $ 4.4 Billion |
| Compound Annual Growth Rate | 2.9% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Allergan PLC
- Basilea Pharmaceutica Ltd.
- Merck & Co., Inc.
- Pfizer, Inc.
- The Medicines Company
- Theravance Biopharma, Inc.
